Published in J Crohns Colitis on August 23, 2012
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut (2001) 10.07
Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med (1990) 6.87
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest (2004) 3.90
Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A (2000) 3.36
Defective inflammatory response in interleukin 6-deficient mice. J Exp Med (1994) 2.92
Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology (1994) 2.55
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med (1998) 2.54
A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol (1976) 2.42
Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol (1996) 2.21
AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology (2010) 2.09
Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem (1988) 2.04
Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost (2005) 1.96
Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest (1991) 1.85
Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol (2003) 1.81
The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J (2002) 1.70
The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J Biol Chem (2004) 1.64
Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem (2001) 1.58
Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest (1997) 1.49
Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease. J Clin Pathol (2003) 1.47
Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1. J Cell Biochem (2004) 1.31
Epidemiology of colorectal liver metastases. Surg Oncol (2007) 1.29
Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis (2010) 1.28
Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. J Biol Chem (1990) 1.24
Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol (2001) 1.23
mRNA and micro-RNA expression analysis in laser-capture microdissected prostate biopsies: valuable tool for risk assessment and prevention trials. Exp Mol Pathol (2009) 1.17
The plasminogen activator inhibitor "paradox" in cancer. Immunol Lett (2008) 1.16
Augmentation of proliferation of vascular smooth muscle cells by plasminogen activator inhibitor type 1. Arterioscler Thromb Vasc Biol (2006) 1.15
Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer (2000) 1.15
Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des (2003) 1.14
Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease. Inflamm Bowel Dis (2010) 1.12
Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth. J Cell Biol (2001) 1.12
Hypoxia-inducible factor-1α mediates TGF-β-induced PAI-1 production in alveolar macrophages in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2011) 1.11
Microglial tissue plasminogen activator (tPA) triggers neuronal apoptosis in vitro. Glia (2000) 1.11
Elevated c-Src tyrosine kinase activity in premalignant epithelia of ulcerative colitis. J Clin Invest (1994) 1.07
Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1. Blood (2002) 1.06
1,25-Dihydroxyvitamin D₃ suppresses inflammation-induced expression of plasminogen activator inhibitor-1 by blocking nuclear factor-κB activation. Arch Biochem Biophys (2010) 1.02
Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol (2003) 1.01
c-Ki-ras mutations in dysplastic fields and cancers in ulcerative colitis. Gastroenterology (1992) 0.99
The effect of plasminogen activator inhibitor type 1 on apoptosis. Thromb Haemost (2008) 0.99
Gene expression analysis of distinct populations of cells isolated from mouse and human inner ear FFPE tissue using laser capture microdissection--a technical report based on preliminary findings. Brain Res (2006) 0.99
Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage. Mol Vis (2003) 0.98
Regulation of plasminogen activator inhibitor-1 mRNA in human endothelial cells. Thromb Haemost (1988) 0.97
Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis. Thromb Haemost (2005) 0.94
The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis. Cancer Res (1999) 0.92
Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway. Neoplasia (2008) 0.91
Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer. Proc Natl Acad Sci U S A (2011) 0.89
Expression of growth factor receptor-encoded mRNA by colonic epithelial cells is altered in inflammatory bowel disease. Dig Dis Sci (1995) 0.89
Insulin-like growth factor binding protein-5 (IGFBP-5) potentially regulates programmed cell death and plasminogen activation in the mammary gland. Adv Exp Med Biol (2000) 0.86
Pp60c-src mediates ERK activation/nuclear localization and PAI-1 gene expression in response to cellular deformation. J Cell Physiol (2003) 0.84
Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells. Exp Cell Res (2004) 0.80
Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med (2012) 16.55
Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology (2006) 4.57
Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol (2012) 4.22
Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci U S A (2007) 3.13
A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol (2010) 3.01
Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol (2006) 2.55
Variation in the detection of serrated polyps in an average risk colorectal cancer screening cohort. Am J Gastroenterol (2010) 2.44
The clinical significance of serrated polyps. Am J Gastroenterol (2010) 2.21
Nonpolypoid neoplastic lesions of the colorectal mucosa. Gastrointest Endosc (2008) 2.09
Factors that affect adherence to surveillance colonoscopy in patients with inflammatory bowel disease. Inflamm Bowel Dis (2013) 2.06
Prevalence of advanced colorectal neoplasia in white and black patients undergoing screening colonoscopy in a safety-net hospital. Ann Intern Med (2013) 2.04
The "cecal patch" in patients with ulcerative colitis. Gastrointest Endosc (2008) 2.03
Endoscopic mucosal resection and endoscopic submucosal dissection. Gastrointest Endosc (2008) 1.95
Overtube use in gastrointestinal endoscopy. Gastrointest Endosc (2009) 1.94
Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol (2004) 1.92
Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology (2006) 1.89
Statins (HMG-CoA reductase inhibitors) decrease postoperative adhesions by increasing peritoneal fibrinolytic activity. Ann Surg (2007) 1.75
Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge. Inflamm Bowel Dis (2011) 1.71
BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am J Surg Pathol (2004) 1.71
Solitary versus multiple carcinoid tumors of the ileum: a clinical and pathologic review of 68 cases. Am J Surg Pathol (2003) 1.66
Narrow band imaging and multiband imaging. Gastrointest Endosc (2008) 1.65
Minimizing occupational hazards in endoscopy: personal protective equipment, radiation safety, and ergonomics. Gastrointest Endosc (2010) 1.57
Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. Cancer Res (2007) 1.56
Risk, mobility or population size? Drivers of technological richness among contact-period western North American hunter-gatherers. Philos Trans R Soc Lond B Biol Sci (2013) 1.50
Recommendations for the reporting of surgically resected specimens of colorectal carcinoma. Virchows Arch (2006) 1.49
Age-related vulnerabilities of older adults with colon adenomas: evidence from Project Prevent. Cancer (2004) 1.48
Bradyarrhythmias during use of the AngioJet system. J Vasc Interv Radiol (2006) 1.43
Primary epiploic appendagitis: an underappreciated diagnosis. A case series and review of the literature. Dig Dis Sci (2004) 1.37
Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. CA Cancer J Clin (2006) 1.33
Pathologic features and clinical significance of "backwash" ileitis in ulcerative colitis. Am J Surg Pathol (2005) 1.30
Hyperplastic (serrated) polyps of the colorectum: relationship of CpG island methylator phenotype and K-ras mutation to location and histologic subtype. Am J Surg Pathol (2004) 1.30
Prevalence and significance of inflammatory bowel disease-like morphologic features in collagenous and lymphocytic colitis. Am J Surg Pathol (2002) 1.30
LPS induces the interaction of a transcription factor, LPS-induced TNF-alpha factor, and STAT6(B) with effects on multiple cytokines. Proc Natl Acad Sci U S A (2005) 1.29
Signaling mechanisms involved in altered function of macrophages from diet-induced obese mice affect immune responses. Proc Natl Acad Sci U S A (2009) 1.25
Induction of colitis causes inflammatory responses in fat depots: evidence for substance P pathways in human mesenteric preadipocytes. Proc Natl Acad Sci U S A (2006) 1.22
Migraine, fibromyalgia, and depression among people with IBS: a prevalence study. BMC Gastroenterol (2006) 1.21
Effect of cognitive activity level on duration of post-concussion symptoms. Pediatrics (2014) 1.21
Hyperplastic polyps, serrated adenomas, and the serrated polyp neoplasia pathway. Am J Gastroenterol (2004) 1.20
A morphometric assessment of the intended function of cached Clovis points. PLoS One (2012) 1.17
Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor. Proc Natl Acad Sci U S A (2008) 1.14
A multinational, internet-based assessment of observer variability in the diagnosis of serrated colorectal polyps. Am J Clin Pathol (2007) 1.12
Reinterpretation of histology of proximal colon polyps called hyperplastic in 2001. World J Gastroenterol (2009) 1.11
Neurokinin-1 receptor and substance P messenger RNA levels increase during intraabdominal adhesion formation. J Surg Res (2002) 1.11
Endoscopic findings and their clinical correlations in patients with symptoms after gastric bypass surgery. Gastrointest Endosc (2003) 1.11
Recommendations for the reporting of surgically resected specimens of colorectal carcinoma. Hum Pathol (2007) 1.11
A neurokinin 1 receptor antagonist decreases postoperative peritoneal adhesion formation and increases peritoneal fibrinolytic activity. Proc Natl Acad Sci U S A (2004) 1.11
Determinants of colorectal cancer screening in women undergoing mammography. Am J Gastroenterol (2003) 1.10
Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon. Inflamm Bowel Dis (2009) 1.10
Clostridium difficile infection in the inflammatory bowel disease patient. Inflamm Bowel Dis (2013) 1.09
Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation. Ann N Y Acad Sci (2010) 1.09
Successful use of adalimumab (Humira) for Crohn's disease in pregnancy. Inflamm Bowel Dis (2006) 1.09
A critical role for the E3-ligase activity of c-Cbl in VEGFR-2-mediated PLCgamma1 activation and angiogenesis. Proc Natl Acad Sci U S A (2007) 1.08
Ultrathin endoscopes. Gastrointest Endosc (2010) 1.08
Endoscopic tattooing. Gastrointest Endosc (2010) 1.07
Population size and cultural evolution in nonindustrial food-producing societies. PLoS One (2013) 1.07
Prevalence and predictors of multiple behavioral risk factors for colon cancer. Prev Med (2005) 1.07
Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape. Cancer (2002) 1.07
Endoscopic hemostatic devices. Gastrointest Endosc (2009) 1.05
Prevalence and prognostic significance of acinar cell differentiation in pancreatic endocrine tumors. Am J Surg Pathol (2002) 1.05
NF-kappaB activation precedes increases in mRNA encoding neurokinin-1 receptor, proinflammatory cytokines, and adhesion molecules in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci (2005) 1.04
The prevalence of undiagnosed concussions in athletes. Clin J Sport Med (2013) 1.04
Electrokinetic molecular separation in nanoscale fluidic channels. Lab Chip (2005) 1.03
Hyperactivated B cells in human inflammatory bowel disease. J Leukoc Biol (2009) 1.03
Functional consequences of alteration of N-linked glycosylation sites on the neurokinin 1 receptor. Proc Natl Acad Sci U S A (2007) 1.02
Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis. J Allergy Clin Immunol (2011) 1.02
Pragmatic classification of superficial neoplastic colorectal lesions. Gastrointest Endosc (2009) 1.02
Clinical and neuroinflammatory responses to meningoencephalitis in substance P receptor knockout mice. Brain (2003) 1.02
Colonoscopy preparation. Gastrointest Endosc (2009) 1.01
Pediatric patients with untreated ulcerative colitis may present initially with unusual morphologic findings. Am J Surg Pathol (2004) 1.00
Treatment of choice for acute severe steroid-refractory ulcerative colitis is colectomy. Inflamm Bowel Dis (2009) 1.00
Liposomal extended-release bupivacaine for postsurgical analgesia. Patient Prefer Adherence (2013) 0.99
Signaling mechanisms in the restoration of impaired immune function due to diet-induced obesity. Proc Natl Acad Sci U S A (2011) 0.98
Crohn's disease after gastric bypass surgery for morbid obesity: is there an association? Inflamm Bowel Dis (2005) 0.98
Practical limitations of bioresorbable membranes in the prevention of intra-abdominal adhesions. J Gastrointest Surg (2008) 0.97
A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis (2006) 0.97
CT findings of rupture, impending rupture, and contained rupture of abdominal aortic aneurysms. AJR Am J Roentgenol (2007) 0.97
Biliary and pancreatic stone extraction devices. Gastrointest Endosc (2009) 0.96
Endoscopic retrieval devices. Gastrointest Endosc (2009) 0.95
Systemic Toll-like receptor ligands modify B-cell responses in human inflammatory bowel disease. Inflamm Bowel Dis (2010) 0.95
Immunization rates and vaccine beliefs among patients with inflammatory bowel disease: an opportunity for improvement. Inflamm Bowel Dis (2014) 0.95
Female gender and other factors predictive of a limited screening flexible sigmoidoscopy examination for colorectal cancer. Am J Gastroenterol (2003) 0.95
Hyperplastic/serrated polyposis in inflammatory bowel disease: a case series of a previously undescribed entity. Am J Surg Pathol (2008) 0.94
A neurokinin 1 receptor antagonist reduces an ongoing ileal pouch inflammation and the response to a subsequent inflammatory stimulus. Am J Physiol Gastrointest Liver Physiol (2003) 0.94
Confocal laser endomicroscopy. Gastrointest Endosc (2009) 0.94
Endocytoscopy. Gastrointest Endosc (2009) 0.93
Interventional EUS. Gastrointest Endosc (2010) 0.92
Devices to improve colon polyp detection. Gastrointest Endosc (2011) 0.92
Enteral nutrition access devices. Gastrointest Endosc (2010) 0.92